switching from semaglutide to tirzepatide results Switch Early Dose Escalation of Tirzepatide

For pharmaceutical companies, investors, healthcare providers, payers, and market research teams, the key question is no longer whether GLP-1 drugs will remain important

Journal reference: Huang, Y.-N., Liu, K.-W., Li, P.-H., Chen, J.-C., Meyerowitz-Katz, G., Su, P.-H., & Huang, C.-C

In the OASIS 4 phase 3 trial, once-daily oral semaglutide at a dose of 25 mg resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity

Cold amplifies contrast benefits but is optional

100% bioavailability means every single bit of the compound gets into your bloodstream to do its job

Medications that have the potential to augment the hypoglycemic effects of semaglutide include beta-blockers, monoamine oxidase inhibitors, androgens, quinolones, salicylates, selective serotonin reuptake inhibitors, and other antidiabetic medications